ATAI Life Sciences NV (NAS:ATAI)
$ 1.67 -0.01 (-0.6%) Market Cap: 279.57 Mil Enterprise Value: 195.80 Mil PE Ratio: 0 PB Ratio: 1.25 GF Score: 26/100

Atai Life Sciences N.V. - Special Call Transcript

Jan 18, 2022 / 05:00PM GMT
Release Date Price: $5.39 (-9.56%)
Srinivas G. Rao
Atai Life Sciences N.V. - Co-Founder & Chief Scientific Officer

Good morning, everybody, and welcome to Atai's webinar focused on the Cognitive Impairment Associated with Schizophrenia. I'd like to thank everybody for joining both our speakers, Matt and Rich as well as the audience members. The goals of today's call or webinar are really twofold.

The first is to provide some -- to provide a little more clarity, a little bit more color on the results that we announced last year -- late last year on RL-007 and the initial proof of mechanism trial of this compound in schizophrenia and cognitive impairment associated with schizophrenia in particular. We talked a little bit about the EEG results that we found there as well as some of the symptomatic benefits that we're seeing. We, again, want to give you a little bit more color there and also provide a touch upon some of the ERP results that were down there.

What's equally important, however, is that we want to provide some context for these results and really give the audience a little bit more information on the

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot